
USA - NASDAQ:ADYX -
The current stock price of ADYX is 3.61 null. In the past month the price decreased by -50.75%.
Adynxx Inc. is a clinical-stage biopharmaceutical company. It is focused on therapeutics for the treatment of pain and inflammatory diseases. Adynxx Inc., formerly known as Alliqua BioMedical Inc., is based in San Francisco, United States.
Adynxx Inc.
2150 CABOT BLVD WEST SUITE B
LANGHORNE PA 19047
CEO: David Johnson
Phone: 215-702-8550
Adynxx Inc. is a clinical-stage biopharmaceutical company. It is focused on therapeutics for the treatment of pain and inflammatory diseases. Adynxx Inc., formerly known as Alliqua BioMedical Inc., is based in San Francisco, United States.
The current stock price of ADYX is 3.61 null. The price decreased by -39.23% in the last trading session.
ADYX does not pay a dividend.
ADYX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Adynxx Inc. (ADYX) has a market capitalization of 3.01M null. This makes ADYX a Nano Cap stock.
You can find the ownership structure of Adynxx Inc. (ADYX) on the Ownership tab.
ChartMill assigns a fundamental rating of 2 / 10 to ADYX. While ADYX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ADYX reported a non-GAAP Earnings per Share(EPS) of -38.93. The EPS decreased by -43.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -379.83% | ||
| ROA | -83.16% | ||
| ROE | -113.96% | ||
| Debt/Equity | N/A |